FACIT Builds on Commercialization Momentum by Attracting Experienced Executive-in-Residence

Anil Amlani expands FACIT’s oncology expertise in medical device sector

TORONTO, ON (June 20, 2017) — FACIT is pleased to announce the appointment of Anil Amlani, CPA, as an Executive-in-Residence (EIR) to guide and support emerging oncology investment and management activities in the Medical Device sector. Mr. Amlani joins FACIT’s team of EIRs that possess strong leadership, commercial and fund raising experience in various technology sectors in life sciences. The appointment of Mr. Amlani broadens the available expertise to provide critical senior management and leadership to create and nurture FACIT start-ups in Ontario.

“FACIT creates and seeds growth companies with a hands-on approach to cultivate sustainable biotechnology start-ups in Ontario, as we have done successfully in the past with companies like Turnstone Biologics, Fusion Therapeutics, and more recently Propellon Therapeutics,” said David O’Neill, Vice President of Business Development at FACIT. “We welcome Anil to the team and will benefit from his extensive experience in the medical device sector. FACIT and its entrepreneur partners can target this market with confidence.”

Prior to joining FACIT, Mr. Amlani held several executive roles including CEO and CFO (VisualSonics), COO and CFO (MDS Proteomics), and CCO (Fujifilm Sonosite). He has led the formation and execution of successful corporate strategies, merger and acquisitions, EBIT growth, restructuring, achievement of significant operational efficiencies, global geographic expansions, and new product introductions. He has also completed over $500M in financings, as well as significant exits with Cancom/StarChoice to Shaw ($675M), VisualSonics (US $67.9M) to Sonosite, and Sonosite to Fujifilm (US $995M).

“Having worked with successful commercial enterprises in both North America and Asia, I have a good appreciation of the challenges emerging companies face in competing for investment and scaling operations,” said Mr. Amlani. “Very few places in the world combine the translational model and commercial expertise as robustly as FACIT and their strategic partner, the Ontario Institute for Cancer Research. I am excited to join the team as I believe this thriving model will positively impact investors in growth companies and most importantly, better care for patients with cancer.”

About the Fight Against Cancer Innovation Trust (FACIT)

Established by the Ontario Institute for Cancer Research (OICR) as a strategic partner to accelerate commercialization of oncology innovations, the Fight Against Cancer Innovation Trust (FACIT) leads these innovations from the lab to the marketplace to benefit patients, researchers, investors and the Ontario economy. For more information, please visit the website at facit.ca or email info@facit.ca.


Connie Chen, PhD, Director of Business Intelligence and Strategy, FACIT


Download FACIT NR_Addition of EIR AAmlani_2017 0620_FINAL.pdf (278.22 KB)


FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.



With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.